Biotech | January 07, 2022
Lilly and Entos collaborate for therapies in multiple neurologic indications
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
The combination rapid antigen test quickly differentiates between SARS-CoV-2 and influenza viruses A and B infections, with results ready in less than 30 minutes, allowing informed decisions on patient and pandemic management decisions
The company is marketing the kit under the brand name CoviFind and it can detect the infection in 15 minutes
First-of-its-kind Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics
The ground-breaking project, led by Genomics England and NHS England, was established in 2013 to sequence 100,000 whole genomes from NHS patients and their families
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
The drug is being developed at lab scale for the first-line of treatment of Covid-19
India’s first gender-neutral HPV vaccine to help reduce HPV -related disease burden in Indian girls, women and boys
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes
Subscribe To Our Newsletter & Stay Updated
